<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00438009</url>
  </required_header>
  <id_info>
    <org_study_id>V937-003</org_study_id>
    <secondary_id>PAH HREC identifier 2006/49</secondary_id>
    <secondary_id>PSX-X03</secondary_id>
    <nct_id>NCT00438009</nct_id>
  </id_info>
  <brief_title>A Safety Study of Two Intratumoural Doses of Coxsackievirus Type A21 in Melanoma Patients (PSX-X03)</brief_title>
  <official_title>A Phase I, Open Label, Cohort Study of Two Doses of Cavatak (Coxsackievirus Type A21) Given Intratumourally in Stage IV Melanoma Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Viralytics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Viralytics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the safety and tolerability of two doses of&#xD;
      Coxsackievirus A21, administered 48 hours apart into a superficial melanoma tumour.&#xD;
&#xD;
      Injected and non-injected tumours will be observed regarding change in tumour size.&#xD;
&#xD;
      Coxsackievirus A21 (CVA21) is a naturally occurring virus, that is known to cause self&#xD;
      limiting upper respiratory infections. CVA21 has been shown in cell culture to infect and&#xD;
      kill human melanoma cancer cell lines. This property of CVA21 is due to the specific&#xD;
      receptors CVA21 uses in order to attach to, and infect a cell. The 2 receptors CVA21 uses to&#xD;
      infect a cell are Intracellular Adhesion Molecule 1 (ICAM-1) and Decay Accelerating Factor.&#xD;
      Both of these surface proteins are expressed on melanoma cell lines as well as human melanoma&#xD;
      tumours. Animal models of human melanoma tumours have demonstrated that CVA21 injection&#xD;
      either intratumour or intravenous causes infection in the tumours, resulting in reduction of&#xD;
      tumour size and growth.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 16, 2007</start_date>
  <completion_date type="Actual">August 28, 2009</completion_date>
  <primary_completion_date type="Actual">August 28, 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of two doses of Coxsackievirus A21 administered intratumourally.</measure>
    <time_frame>Days 1, 3, 6, 8, 10, 13, 17, 24, 38, 52, 87</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine clinical response of the injected tumour</measure>
    <time_frame>Days 24, 52, 87</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine clinical response in non-injected tumours using RECIST criteria</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time course and quantify CVA21 viremias</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine time course to elimination of CVA21</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine time course, frequency as well as quantify the development of anti-CVA21 antibodies</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Stage IV Melanoma</condition>
  <arm_group>
    <arm_group_label>CAVATAK</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Coxsackievirus A21</intervention_name>
    <description>Two doses of drug, separated by 48 hours</description>
    <arm_group_label>CAVATAK</arm_group_label>
    <other_name>CAVATAK</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Greater than 18 years of age.&#xD;
&#xD;
          -  One subcutaneous melanoma metastatic deposit, 2.0 to 5.0 cm in diameter, accessible to&#xD;
             3mm punch biopsy and injection, may be tumour infiltrated lymph node.&#xD;
&#xD;
          -  Melanoma stage IV.&#xD;
&#xD;
          -  3mm punch biopsy of the selected tumour must be expressing ICAM-1 and DAF.&#xD;
&#xD;
          -  Absence of circulating antibodies to CVA21 (titre &lt; 1:16)&#xD;
&#xD;
          -  Patients must have adequate hematological, renal and hepatic function&#xD;
&#xD;
          -  Failed or refused standard treatment (s)&#xD;
&#xD;
          -  Patients are able and willing to provide signed/informed consent to participate in the&#xD;
             study.&#xD;
&#xD;
          -  Fertile males and females must agree to the use of adequate form of contraception, eg.&#xD;
             Condoms for males&#xD;
&#xD;
          -  Negative pregnancy test is required for female patients of child bearing potential.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Mucosal or ocular tumour&#xD;
&#xD;
          -  Presence of CNS tumour&#xD;
&#xD;
          -  Radiotherapy to the injection tumour site.&#xD;
&#xD;
          -  Prior local radiotherapy without subsequent nodule progression&#xD;
&#xD;
          -  Chemotherapy within 4 weeks of screening visit.&#xD;
&#xD;
          -  ECOG score greater than 1.&#xD;
&#xD;
          -  Life expectancy less than 3 months.&#xD;
&#xD;
          -  Pregnancy or breast feeding.&#xD;
&#xD;
          -  Primary or secondary immunodeficiency, including immuno-suppressive doses of&#xD;
             corticosteroids (prednisolone greater than 7.5 mg/day, or other immuno-suppressive&#xD;
             drugs such as cyclosporine, azothioprine, interferons, within the 4 weeks prior to&#xD;
             screening visit.&#xD;
&#xD;
          -  Positive serology for HIV, Hepatitis B virus or Hepatitis C virus&#xD;
&#xD;
          -  Full dose anticoagulation, or a history of bleeding diathesis, or history of difficult&#xD;
             to control bleeding in the month before screening visit.&#xD;
&#xD;
          -  Previous splenectomy.&#xD;
&#xD;
          -  Presence of uncontrolled infection.&#xD;
&#xD;
          -  Presence of unstable neurological disease&#xD;
&#xD;
          -  Any uncontrolled medical condition that in the opinion of the Investigator is likely&#xD;
             to place the patient at unacceptable risk during the study or reduce their ability to&#xD;
             complete the study&#xD;
&#xD;
          -  Participation in another study requiring administration of an investigational drug or&#xD;
             biological agent within the last 4 weeks prior to screening visit.&#xD;
&#xD;
          -  Known allergy to treatment medication or excipients&#xD;
&#xD;
          -  Any other medical or psychological condition that would preclude participation in the&#xD;
             study or compromise ability to give informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <reference>
    <citation>Shafren DR, Au GG, Nguyen T, Newcombe NG, Haley ES, Beagley L, Johansson ES, Hersey P, Barry RD. Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21. Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):53-60.</citation>
    <PMID>14734451</PMID>
  </reference>
  <reference>
    <citation>Au GG, Lindberg AM, Barry RD, Shafren DR. Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21. Int J Oncol. 2005 Jun;26(6):1471-6.</citation>
    <PMID>15870858</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>February 19, 2007</study_first_submitted>
  <study_first_submitted_qc>February 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2007</study_first_posted>
  <last_update_submitted>June 26, 2019</last_update_submitted>
  <last_update_submitted_qc>June 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>coxsackievirus type a21</keyword>
  <keyword>oncolytic virus</keyword>
  <keyword>melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coxsackievirus Infections</mesh_term>
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

